$LLY

Pharmaceutical companies have invested over $5 billion in psychedelic-derived medicines, with Eli Lilly, AbbVie, and Otsuka acquiring firms like AtaiBeckley, Gilgamesh, and Transcend. Compass Pathways' COMP360 is in FDA review for a 2027 launch. The market is projected to reach $11.8B-$14.9B by 2034-2035, driven by high demand for depression treatments. Companies are developing short-acting analogs to reduce clinic stay times.

U.S. stocks fell for a third day, with the Nasdaq down 1.3%. Semiconductor stocks plunged, led by SK Hynix (-9.2%) and Micron (-7.02%). Rising Treasury yields and inflation concerns weighed on markets. Apple (+1.45%) and Microsoft (+0.27%) gained, while Meta (-4.45%) and Tesla (-0.72%) declined. Oil prices rose, and the VIX increased to 15.84.

Eli Lilly (LLY) shares rose 3.6% after acquiring Alzheimer's drug rights for $10M upfront, with potential $1B in milestones, and a $370M ion channel collaboration. Q2 revenue surged 47.7% to $22.97B, beating estimates, driven by Mounjaro and Zepbound sales. Full-year revenue guidance raised to $86B midpoint. Stock near 52-week high at $1,227.

Jonsson Patrik (EVP & President, LLY Int'l) sold 6,500 shares of ELI LILLY & Co (LLY) at $1175.10 ($7.64M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Eli Lilly has renewed its global partnership with Veeva Systems, adopting Veeva's Vault CRM platform to streamline commercial operations and leverage AI. The move extends their existing relationship and reflects growing industry confidence in AI-driven commercial platforms. According to Eli Lilly, Vault CRM will help deliver medicines more efficiently. Veeva's CEO highlighted the long-standing collaboration and the success of Vault CRM with over 180 customers in 100+ countries.

Eli Lilly Canada warned Canadians about online sales of “unapproved and illegal” retatrutide, saying it is not approved by Health Canada or any regulator and cannot be lawfully sold. Lilly Canada cites phase 3 trial weight-loss results and says it has filed six U.S. lawsuits and flagged hundreds of operators. Reuters reports U.S. seizures of illicit obesity/diabetes drugs.

A retrospective chart review in Diabetes Technology & Therapeutics compared 106 adults with type 1 diabetes using tirzepatide (Mounjaro/Zepbound, Eli Lilly) for at least 1 year with 85 controls. New-onset diabetic retinopathy occurred in 25.6% vs 29.2%. HbA1c fell more with tirzepatide (6.3% vs 7.2%), and rapid HbA1c declines (≥0.5 points) were linked to higher retinopathy rates.

Eli Lilly (LLY) shares rose about 2% and edged up after-hours after it reported late-stage trials showing its oral GLP-1 pill Foundayo (orforglipron) improved blood sugar and weight in type 2 diabetes. Lilly said Foundayo beat Novo Nordisk’s semaglutide and AstraZeneca’s dapagliflozin and placebo in three trials, with similar safety.

Eli Lilly is running two Phase III programs for brenipatide in major depressive disorder, including RENEW-MDD-1 (enrolling about 1,000 adults since Feb. 9, 2026) and RENEW-MDD-2, disclosed via Chinese filings Aug. 17. Trials target relapse prevention over 12+ months and do not require obesity or diabetes. Lilly’s Q2 2026 revenue rose 48% to $23.0B, led by Mounjaro and Zepbound.

CNBC’s Investing Club says pharma stocks Eli Lilly and Johnson & Johnson rose as new prescription data from Leerink (using IQVIA) showed Lilly’s oral GLP-1 Foundayo prescriptions up 14% to about 38,900 for week ending Aug. 7, while Novo Nordisk’s oral Wegovy fell 5% to about 163,000. Leerink also cited J&J’s oral IL-23 inhibitor Icotyde prescription acceleration. Rates and software stocks were mixed.